Face/neck respond fastest: perifollicular islands in 4–8 weeks, meaningful F-VASI drops by 8–12 weeks—best as nightly monotherapy or with excimer 308 nm.
Trunk/proximal limbs: slower curve; add NB-UVB 311 nm 2–3×/wk and keep tacrolimus on off-light days for synergy.
Acral (hands/feet): lowest yield with monotherapy; prioritize excimer to rims + tacrolimus; consider surgery when stable focal plaques persist.
Safety: no atrophy risk on face/folds; manage transient stinging with emollient-first technique; long-term maintenance 2–3 nights/week helps prevent relapse (see TRM maintenance).
Why Calcineurin Inhibitors in Vitiligo
Tacrolimus down-modulates T-cell–driven melanocyte damage at the rim and supports repigmentation from follicular reservoirs. On face/folds it replaces chronic steroids to avoid atrophy and telangiectasia.
Efficacy by Zone
Table 1. Expected response with tacrolimus 0.1% by site.
Zone
Time to first islands
12-week expectation
24-week expectation
Pearls
Face/Neck
4–8 wks
Visible fill-in; F-VASI ↓
Confluence in periorificial/hairy areas
Nightly use; add excimer for rims
Trunk/Proximal Limbs
8–12 wks
Islands; T-VASI modest ↓
Consolidation with NB-UVB
Short steroid pulse → switch to tacrolimus
Acral (Hands/Feet)
12+ wks (variable)
Limited without light
Better with excimer focus
Friction control; consider surgery if stable
Folds/Lips/Eyelids
4–8 wks
Good cosmetic gain
Maintain 2–3 nights/week
Preferred over steroids long-term
Combining with Light
NB-UVB 311 nm: keep tacrolimus on non-light days; recheck at 8–12 weeks (photos + VASI).
Excimer 308 nm: ideal for face rims, periorificial sites, and acral borders; space tacrolimus by ≥8–12 h from sessions.